

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-102330-PIP01-26

Scope of the Application

Active Substance(s)

Vimseltinib

Condition(s)

Treatment of tenosynovial giant cell tumour

Pharmaceutical Form(s)

Capsule, hard

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Deciphera Pharmaceuticals (Netherlands) B.V.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Deciphera Pharmaceuticals (Netherlands) B.V. submitted to the licensing authority on 18/02/2026 17:27 GMT an application for a Waiver

The procedure started on 25/02/2026 18:26 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102330-PIP01-26

Of 27/02/2026 11:49 GMT

On the adopted decision for Vimseltinib (MHRA-102330-PIP01-26) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s).

This decision applies to a Waiver for Vimseltinib, Capsule, hard , ORAL USE .

This decision is addressed to Deciphera Pharmaceuticals (Netherlands) B.V., Strawinskylaan 3051, Amsterdam, NETHERLANDS, 1077 ZX

ANNEX I

1. Waiver

1.1 Condition:

Treatment of tenosynovial giant cell tumour The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age. Pharmaceutical form(s): Capsule, hard Route(s) of administration: ORAL USE Reason for granting waiver: For paediatric population from birth to subset of pre-pubertal children, on the grounds that the specific medicinal product is likely to be unsafe. For paediatric population from post-pubertal children to less than 18 years of age, on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable

2.2 Indication(s) targeted by the PIP:

Not applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable

2.4 Pharmaceutical Form(s):

Not applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	

